Business
IM Cannabis to Launch WAGNERS Brand in Germany
IM Cannabis expects to export premium, indoor-grown Canadian cannabis in 2022 to the rapidly evolving German medical cannabis marketTORONTO, ON, GLIL YAM,
About this update from Im Cannabis Corp.
[{"type":"text","content":"IM Cannabis expects to export premium, indoor-grown Canadian cannabis in 2022 to the rapidly evolving German medical cannabis marketTORONTO, ON, GLIL YAM, ISRAEL and BAD OLDESLOE, GERMANY / ACCESSWIRE / December 7, 2021 / IM Cannabis Corp. (the \"Company\" or \"IM Cannabis\") (CSE:IMCC, NASDAQ:IMCC), a global cannabis company with operations in Israel, Canada, and Germany is pleased to announce plans to launch its popular Canadian WAGNERS brand in the German medical cannabis market in 2022 and begin exports of premium, indoor-grown dried flower from IMC Canada's cultivation facility in 2022, subject to regulatory approval. These plans are consistent with the Company's vertically integrated, multi-country strategy and follow the Company's recently announced launch of WAGNERS in Israel and the receipt of an import permit for Canadian cannabis products from the Israeli Ministry of Health.To learn more about WAGNERS, please visit WAGNERS - Well Made Weed (wagnersweed.com)1Oren Shuster, CEO of IM Cannabis stated, \"With the rapid growth in demand for premium indoor-grown Canadian cannabis and an increasing number of German medical patients not relying on government re-imbursement, we are excited to launch our popular WAGNERS brand to medical patients in Germany. We continue to lay our foundation in Germany, currently one of the largest medical cannabis markets in the world, which is expected to rapidly expand as Germany's new elected government enact broad regulatory reform of cannabis use. Leveraging our global supply chain, IM Cannabis continues to focus on growing our business substantially in Germany in the near term and being well-positioned through brand recognition for eventual regulatory reform.\"IM Cannabis' Global Infrastructure for International ShipmentsIM Cannabis operates in Germany through Adjupharm GmbH, the Company's fully licensed EU-GMP subsidiary (\"Adjupharm\" or \"IMC Germany\"), which recently completed construction of a new, state-of-the-art logistics center that will allow the Company to execute all aspects of its supply chain including the repackaging of bulk cannabis. The Company expects that the logistics center will augment the Company's distribution capabilities. Additionally, the Company's operations in Germany are expected to serve as the center of a broader long-term European strategy. Since being acq...